Compelling experimental and clinical evidence also demonstrated that EGFR signaling actively regulates the tumor immune microenvironment and that EGFR inhibition prompts not only an increase in TILs and expression of immune checkpoints, but also serves as a promising immunotherapy sensitizer [102,103,104,105]. The gene discussed is EGFR; the disease is neoplasm.